Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWINSS: iscalimab in Sjögren's syndrome
2018-004476-35Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iscalimab in Sjögren's syndrome (6 arms), sponsored by Novartis. Primary endpoint: Change in ESSDAI score from baseline at 24 weeks. Started May 2019; status: completed.
02
Drugs
iscalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2018-004476-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004476-35.